Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Blood (2025) 146 (23): 2758–2764.

https://doi.org/10.1182/blood.2025028823

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Wei Li, Chuanxu Liu, Wenyang Huang, Ou Bai, Lihong Liu, Zengjun Li, Wei Xu, Wei Zhang, Liping Su, Kaiyang Ding, Luqun Wang, Guohui Cui, Hongmei Jing, Jianli Wang, Ziheng Guo, Weili Zhao, Huilai Zhang

Blood (2025) 146 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2025-7135

Published: 2025

Journal Articles

Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL)

Li Wang, Jianzhen Shen, Yaohui Huang, Jing Bao, Lin Shen, Pengpeng Xu, Shu Cheng, Hongming Zhu, Weili Zhao

Blood (2025) 146 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2025-3599

Published: 2025

Journal Articles

Single-cell transcriptomic profiling reveals tumor-intrinsic heterogeneity and immune-microenvironment dynamics in the order trial for mantle-cell lymphoma

Lu Jiang, Xiaozhong Shen, Weili Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 1792.

https://doi.org/10.1182/blood-2025-1792

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Jia Li, Wei Zhang, Huaqing Wang, Weili Zhao, Chuanxu Liu, Kaiyang Ding, Wenyang Huang, Zengjun Li, Xiaobo Wang, Hongmei Jing, Zheng Ge, Jianli Wang, Ziheng Guo, Huilai Zhang, Ou Bai

Blood (2025) 146 (Supplement 1): 5466.

https://doi.org/10.1182/blood-2025-5466

Published: 2025

Journal Articles

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

Blood (2025) 146 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2025-1574

Published: 2025

Journal Articles

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2025-3684

Published: 2025

Journal Articles

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Blood (2025) 146 (Supplement 1): 6293.

https://doi.org/10.1182/blood-2025-6293

Published: 2025

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

Polatuzumab Vedotin, Zanubrutinib, Rituximab and Lenalidomide (Pola-ZR2) Regimen in the Treatment of Unfit or Frail Patients with Diffuse Large B-Cell Lymphoma

Ziyang Shi, Qing Shi, Weili Zhao, Li Wang

Blood (2024) 144 (Supplement 1): 4492.

https://doi.org/10.1182/blood-2024-204808

Published: 2024

Journal Articles

Mechanism and Updated Results of Selinexor in Combination with Salvage Regimen for Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients with TP53 Alterations

Ying Fang, Weili Zhao, Wang Li

Blood (2024) 144 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2024-202789

Published: 2024

Journal Articles

Over-Expression of GATA3 in Large B-Cell Lymphoma Predicts Better Prognosis

Fan Zhang, Jiaying Liu, Yuting Dai, Di Fu, Yige Shen, Li Wang, Weili Zhao

Blood (2024) 144 (Supplement 1): 6272.

https://doi.org/10.1182/blood-2024-204855

Published: 2024

Journal Articles

Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Shu Cheng, Li Wang, Pengpeng Xu, Muchen Zhang, Weili Zhao

Blood (2024) 144 (Supplement 1): 4502.3.

https://doi.org/10.1182/blood-2024-204749

Published: 2024

Journal Articles

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Lin Shen, Jing Bao, Lihong Shou, Ying Lu, Qi Zhu, Li Wang, Weili Zhao

Blood (2024) 144 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2024-204547

Published: 2024

Journal Articles

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

Tianyuan Xu, Nan Wang, Rui Sun, Ruichi Li, Di Fu, Yan Zhao, Pengpeng Xu, Shu Cheng, Li Wang, Wei Tang, Zhong Zheng, Weili Zhao

Blood (2024) 144 (Supplement 1): 6200.

https://doi.org/10.1182/blood-2024-204775

Published: 2024

Journal Articles

A China Survey on the Insights of Patients Living with Follicular Lymphoma: The Real-World Patient Journey Analysis

Yang He, Huilai Zhang, Bing Xu, Zengjun Li, Zheng Song, Qiuhui Jiang, Hui Wang, Weili Zhao

Blood (2024) 144 (Supplement 1): 7622.

https://doi.org/10.1182/blood-2024-206977

Published: 2024

Journal Articles

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Siyuan Chen, Li Wang, Pengpeng Xu, Shu Cheng, Wei Tang, Wen Wu, Mengmeng Ji, Zhong Zheng, Zixun Yan, Lingshuang Sheng, Yige Shen, Weili Zhao

Blood (2024) 144 (Supplement 1): 6553.

https://doi.org/10.1182/blood-2024-203842

Published: 2024

Journal Articles

Transient Activation of PIEZO1 Mechanosensitive Channel Facilitates Ex Vivo expansion of Hematopoietic Stem Cells

Qiwei Wang, Weili Zhao, He Huang, Pengxu Qian

Blood (2024) 144 (Supplement 1): 2649.

https://doi.org/10.1182/blood-2024-193734

Published: 2024

Journal Articles

SNORD113-114 Cluster Maintains Hematopoietic Stem Cell Self-Renewal Via Orchestrating the Translation Machinery

Hui Wang, Zhaoru Zhang, Yingli Han, Weili Zhao, Penglei Jiang, Bing Liu, Jia Yu, Fang Wang, Pengxu Qian

Blood (2024) 144 (Supplement 1): 438.

https://doi.org/10.1182/blood-2024-199496

Published: 2024

Journal Articles

The Clinical Efficacy and Safety of Glofitamab in Chinese Relapsed or Refractory Large B-Cell Lymphoma

Yingyu Dong, Weili Zhao, Li Wang

Blood (2024) 144 (Supplement 1): 6522.

https://doi.org/10.1182/blood-2024-204848

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL)

Single-cell transcriptomic profiling reveals tumor-intrinsic heterogeneity and immune-microenvironment dynamics in the order trial for mantle-cell lymphoma

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Polatuzumab Vedotin, Zanubrutinib, Rituximab and Lenalidomide (Pola-ZR2) Regimen in the Treatment of Unfit or Frail Patients with Diffuse Large B-Cell Lymphoma

Mechanism and Updated Results of Selinexor in Combination with Salvage Regimen for Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients with TP53 Alterations

Over-Expression of GATA3 in Large B-Cell Lymphoma Predicts Better Prognosis

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

A China Survey on the Insights of Patients Living with Follicular Lymphoma: The Real-World Patient Journey Analysis

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Transient Activation of PIEZO1 Mechanosensitive Channel Facilitates Ex Vivo expansion of Hematopoietic Stem Cells

SNORD113-114 Cluster Maintains Hematopoietic Stem Cell Self-Renewal Via Orchestrating the Translation Machinery

The Clinical Efficacy and Safety of Glofitamab in Chinese Relapsed or Refractory Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only